Media coverage about Novocure (NASDAQ:NVCR) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novocure earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 44.4865525335178 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the headlines that may have impacted Accern’s scoring:
- Novocure (NVCR) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
- Novocure (NVCR) Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- Novocure Ltd (NVCR) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Insider Selling: Novocure Ltd (NVCR) CFO Sells 31,132 Shares of Stock (americanbankingnews.com)
- Here's Why NovoCure Popped 157% in 2017 (finance.yahoo.com)
Shares of Novocure (NASDAQ NVCR) opened at $21.70 on Friday. Novocure has a 52 week low of $6.00 and a 52 week high of $22.90. The company has a quick ratio of 5.30, a current ratio of 5.90 and a debt-to-equity ratio of 0.83. The company has a market cap of $1,940.00 and a price-to-earnings ratio of -26.14.
Novocure (NASDAQ:NVCR) last issued its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.07. The business had revenue of $50.10 million for the quarter, compared to the consensus estimate of $43.45 million. Novocure had a negative net margin of 47.45% and a negative return on equity of 57.68%. The firm’s quarterly revenue was up 130.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.39) EPS. sell-side analysts expect that Novocure will post -0.65 earnings per share for the current fiscal year.
Several brokerages have recently commented on NVCR. Zacks Investment Research downgraded shares of Novocure from a “buy” rating to a “hold” rating in a research note on Saturday. BidaskClub upgraded shares of Novocure from a “hold” rating to a “buy” rating in a research note on Saturday. ValuEngine upgraded shares of Novocure from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Mizuho restated a “buy” rating and issued a $25.00 target price on shares of Novocure in a research note on Friday, December 1st. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Novocure in a research note on Monday, November 20th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $21.13.
In related news, CEO Asaf Danziger sold 15,866 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $22.01, for a total transaction of $349,210.66. Following the transaction, the chief executive officer now owns 774,040 shares in the company, valued at approximately $17,036,620.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Eilon D. Kirson sold 22,269 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $22.01, for a total transaction of $490,140.69. Following the transaction, the insider now owns 63,120 shares in the company, valued at approximately $1,389,271.20. The disclosure for this sale can be found here. In the last quarter, insiders have sold 286,281 shares of company stock worth $5,918,695. 16.70% of the stock is owned by corporate insiders.
NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.
Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.